Top pick: China: Knife attack in Shanghai metro station leaves three injured

Study shows COVID-19 vaccine can help people with heart failure live longer

Just Earth News | @justearthnews | 12 May 2024

Study shows COVID-19 vaccine can help people with heart failure live longer

Photo Courtesy: Unsplash

Heart failure patients who are vaccinated against COVID-19 have an 82% greater likelihood of living longer than those who are not vaccinated, according to research presented today at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC).

Heart Failure is a life-threatening syndrome affecting more than 64 million people worldwide.

“Patients with heart failure should be vaccinated against COVID-19 to protect their health,” said study author Dr. Kyeong-Hyeon Chun of the National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea. “In this large study of patients with heart failure, COVID-19 vaccination was associated with a lower likelihood of contracting the infection, being admitted to hospital because of heart failure, or dying from any cause during a six-month period compared with remaining unvaccinated.”

Previous studies have shown the safety of COVID-19 vaccination in patients with cardiovascular diseases including heart failure, and that COVID-19 outcomes are worse in patients with heart failure compared to those without heart failure.

However, there has been little research on how vaccines work specifically in patients with heart failure.

This nationwide, retrospective study examined the prognosis of heart failure patients according to COVID-19 vaccination status.

This study used the Korean National Health Insurance Service database, which covers nearly all residents of the Republic of Korea, to obtain information on vaccinations and clinical outcomes.

Participants who received two or more doses of COVID-19 vaccine were defined as "vaccinated", and those who were not vaccinated or had received just one dose were defined as "unvaccinated".

The study included 651,127 patients aged 18 years or older with heart failure. The average age was 69.5 years and 50% were women. Of the total study population, 538,434 (83%) were defined as vaccinated and 112,693 (17%) as unvaccinated.

To control for factors that could influence the relationship between vaccination status and outcomes, the researchers performed 1:1 matching of vaccinated and unvaccinated patients according to age, sex, other health conditions (e.g. high blood pressure, diabetes, high cholesterol, etc.), income, and region of residence. This resulted in 73,559 vaccinated patients and 73,559 unvaccinated patients for the comparative analyses.

The median follow-up was six months. Vaccination was associated with an 82% lower risk of all-cause mortality,7 47% lower risk of hospitalisation for heart failure,8 and 13% reduced risk of COVID-19 infection9 compared with no vaccination. Regarding cardiovascular complications, vaccination was associated with significantly lower risks of stroke, heart attack, myocarditis/pericarditis, and venous thromboembolism compared to no vaccination.

Dr. Chun said: “This was the first analysis of COVID-19 vaccine effectiveness in a large population of heart failure patients, and the first to show a clear benefit from vaccination. The study provides strong evidence to support vaccination in patients with heart failure. However, this evidence may not be applicable to all patients with heart failure, and the risks of vaccination should be considered in patients with unstable conditions.”

AstraZeneca admits in court papers that its COVID-19 vaccine can cause rare side effects

AstraZeneca has confirmed in court documents that its COVID-19 vaccine, developed in collaboration with the University of Oxford, can cause a rare side effect called thrombosis with thrombocytopenia syndrome (TTS), according to a report released in a British newspaper.

The vaccine has been admitted amid a class-action lawsuit claiming numerous deaths and injuries, with victims and their families seeking up to £100 million in damages, UNI news agency reported quoting the British newspaper.

According to Telegraph UK, The lawsuit was Initiated by Jamie Scott, a father of two, who suffered a permanent brain injury after developing a blood clot and a bleed on the brain following his vaccination in April 2021.

The legal battle has intensified, with 51 cases now lodged in the High Court, highlighting the devastating impact TTS has had on individuals and families.

Kate Scott, Scott’s wife, told the Telegraph as quoted by UNI, “The medical world has acknowledged for a long time that VITT was caused by the vaccine. It’s only AstraZeneca who have questioned whether Jamie’s condition was caused by the jab.''

“It’s taken three years for this admission to come. It’s progress, but we would like to see more from them and the Government. It’s time for things to move more quickly.

“I hope their admission means we will be able to sort this out sooner rather than later. We need an apology, fair compensation for our family and other families who have been affected. We have the truth on our side, and we are not going to give up.”

AstraZeneca acknowledges a link between the COVID-19 vaccine and vaccine-induced immune thrombocytopenia and thrombosis (VITT) in March 2021, shortly after the vaccine rollout began.